S3 Table. Incidence of ADRs by maximum severity with clofarabine use

	Incidence of ADRs (n=60)				
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Febrile neutropenia	2 (3.33)	2 (3.33)	32 (53.33)	0	2 (3.33)
Nausea	7 (11.67)	22 (36.67)	3 (5.00)	0	0
Vomiting	14 (23.33)	14 (23.33)	5 (8.33)	0	0
Diarrhea	8 (13.33)	9 (15.00)	6 (10.00)	0	0
Stomatitis	0	6 (10.00)	5 (8.33)	0	0
Alanine aminotransferase increased	3 (5.00)	1 (1.67)	6 (10.00)	1 (1.67)	0
Aspartate aminotransferase increased	1 (1.67)	2 (3.33)	6 (10.00)	1 (1.67)	0
Pyrexia	5 (8.33)	5 (8.33)	1 (1.67)	0	0
Headache	2 (3.33)	5 (8.33)	1 (1.67)	0	0
Abdominal pain	2 (3.33)	4 (6.67)	0	0	0
Decreased appetite	0	4 (6.67)	1 (1.67)	0	0
Neutrophil count decreased	0	0	2 (3.33)	3 (5.00)	0
Pruritus	3 (5.00)	0	0	0	0
Neutropenia	1 (1.67)	1 (1.67)	2 (3.33)	0	0
Sepsis	0	0	1 (1.67)	1 (1.67)	2 (3.33)
Rash	1 (1.67)	2 (3.33)	0	0	0
Parainfluenza virus infection	0	1 (1.67)	2 (3.33)	0	0
Mouth ulceration	0	2 (3.33)	0	0	0
Urticaria	0	2 (3.33)	0	0	0
Bone pain	0	2 (3.33)	0	0	0
Myalgia	0	2 (3.33)	0	0	0
Pain in extremity	0	2 (3.33)	0	0	0
Renal tubular disorder	0	2 (3.33)	0	0	0
Pancreatitis	0	0	2 (3.33)	0	0
Device related infection	0	0	2 (3.33)	0	0
Hepatitis	0	0	2 (3.33)	0	0
Hematuria	1 (1.67)	1 (1.67)	1 (1.67)	0	0
Hyperbilirubinemia	1 (1.67)	1 (1.67)	1 (1.67)	0	0
Fatigue	1 (1.67)	1 (1.67)	0	0	0

Cough	1 (1.67)	1 (1.67)	0	0	0
Hemoptysis	1 (1.67)	1 (1.67)	0	0	0
Rhinorrhea	1 (1.67)	1 (1.67)	0	0	0
Oral pain	0	1 (1.67)	1 (1.67)	0	0
Pneumonia	0	0	1 (1.67)	0	1 (1.67)
Lung infection	0	0	1 (1.67)	0	1 (1.67)
Mouth swelling	1 (1.67)	0	0	0	0
Chest pain	1 (1.67)	0	0	0	0
Edema	1 (1.67)	0	0	0	0
Dizziness	1 (1.67)	0	0	0	0
Paresthesia	1 (1.67)	0	0	0	0
Erythema multiforme	1 (1.67)	0	0	0	0
Purpura	1 (1.67)	0	0	0	0
Ocular icterus	1 (1.67)	0	0	0	0
Vulvovaginal pruritus	1 (1.67)	0	0	0	0
Eyelid edema	1 (1.67)	0	0	0	0
Abdominal tenderness	0	1 (1.67)	0	0	0
Cytopenia	0	1 (1.67)	0	0	0
Constipation	0	1 (1.67)	0	0	0
Hematemesis	0	1 (1.67)	0	0	0
Aspergillus infection	0	1 (1.67)	0	0	0
Escherichia infection	0	1 (1.67)	0	0	0
Parotitis	0	1 (1.67)	0	0	0
Sinusitis	0	1 (1.67)	0	0	0
Seizure	0	1 (1.67)	0	0	0
Back pain	0	1 (1.67)	0	0	0
Musculoskeletal pain	0	1 (1.67)	0	0	0
Pain in jaw	0	1 (1.67)	0	0	0
Scrotal pain	0	1 (1.67)	0	0	0
Tachycardia	0	1 (1.67)	0	0	0
Ascites	0	0	1 (1.67)	0	0
Atypical pneumonia	0	0	1 (1.67)	0	0
BK virus infection	0	0	1 (1.67)	0	0

Bacterial sepsis	0	0	1 (1.67)	0	0
Cytomegalovirus infection	0	0	1 (1.67)	0	0
Fungal infection	0	0	1 (1.67)	0	0
Mycoplasma infection	0	0	1 (1.67)	0	0
Upper respiratory tract infection	0	0	1 (1.67)	0	0
Amylase increased	0	0	1 (1.67)	0	0
Blood creatinine increased	0	0	1 (1.67)	0	0
Lipase increased	0	0	1 (1.67)	0	0
Dyspnea	0	0	1 (1.67)	0	0
Pleural effusion	0	0	1 (1.67)	0	0
Hyperglycemia	0	0	1 (1.67)	0	0
Hyperuricemia	0	0	1 (1.67)	0	0
Tumor lysis syndrome	0	0	1 (1.67)	0	0
Cystitis hemorrhagic	0	0	1 (1.67)	0	0
Confusional state	0	0	1 (1.67)	0	0
Hypotension	0	0	1 (1.67)	0	0
White blood cell count decreased	0	0	0	1 (1.67)	0
Septic shock	0	0	0	0	1 (1.67)

MedDRA ver. 20.1. Note: Denominator of percentage is the number of patients. Adverse events are displayed as ‘number of patients (percentage of patients)'. If one patient experienced the same adverse event more than once, the adverse event was counted only once with the most severe category. ADRs, adverse drug reactions; n, total patients analyzed.